Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on Moleculin Biotech Surges 19.5%—What's Fueling the Rally? - AInvest

Moleculin Biotech Surges 19.5%—What's Fueling the Rally?  AInvest

Moleculin Biotech Surges 19.5%—What's Fueling the Rally? - AInvest

Click here to get full coverage on Insider Purchase: Chief Financial Officer of $MBRX Buys 270,270 Shares - Nasdaq

Insider Purchase: Chief Financial Officer of $MBRX Buys 270,270 Shares  Nasdaq

Insider Purchase: Chief Financial Officer of $MBRX Buys 270,270 Shares - Nasdaq

Click here to get full coverage on Favourable Signals For Moleculin Biotech: Numerous Insiders Acquired Stock - simplywall.st

Favourable Signals For Moleculin Biotech: Numerous Insiders Acquired Stock  simplywall.st

Favourable Signals For Moleculin Biotech: Numerous Insiders Acquired Stock - simplywall.st

Click here to get full coverage on Top Cancer Expert Reveals New Insights on Moleculin's Breakthrough Sarcoma Drug Trial Success - Stock Titan

Top Cancer Expert Reveals New Insights on Moleculin's Breakthrough Sarcoma Drug Trial Success  Stock Titan

Top Cancer Expert Reveals New Insights on Moleculin's Breakthrough Sarcoma Drug Trial Success - Stock Titan

Click here to get full coverage on Moleculin Biotech Faces Nasdaq Delisting Warning - TipRanks

Moleculin Biotech Faces Nasdaq Delisting Warning  TipRanks

Moleculin Biotech Faces Nasdaq Delisting Warning - TipRanks

Click here to get full coverage on Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds - PR Newswire

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds  PR Newswire

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds - PR Newswire

Click here to get full coverage on Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ...  Yahoo Finance

Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

Click here to get full coverage on Moleculin Announces $5.9 Million Public Offering - GlobeNewswire

Moleculin Announces $5.9 Million Public Offering  GlobeNewswire

Moleculin Announces $5.9 Million Public Offering - GlobeNewswire

Click here to get full coverage on Moleculin Biotech Gains Approval for Phase 2B/3 AML Study - MSN

Moleculin Biotech Gains Approval for Phase 2B/3 AML Study  MSN

Moleculin Biotech Gains Approval for Phase 2B/3 AML Study - MSN

Click here to get full coverage on Moleculin Secures $5.9M Funding: Major Push for Late-Stage Cancer Drug Development - Stock Titan

Moleculin Secures $5.9M Funding: Major Push for Late-Stage Cancer Drug Development  Stock Titan

Moleculin Secures $5.9M Funding: Major Push for Late-Stage Cancer Drug Development - Stock Titan

Click here to get full coverage on Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML) - PR Newswire

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)  PR Newswire

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML) - PR Newswire

Click here to get full coverage on All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - Yahoo Finance

All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy  Yahoo Finance

All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - Yahoo Finance

Click here to get full coverage on Moleculin Biotech Enters New Stock Offering Agreement - TipRanks

Moleculin Biotech Enters New Stock Offering Agreement  TipRanks

Moleculin Biotech Enters New Stock Offering Agreement - TipRanks

Click here to get full coverage on Moleculin Biotech's 48% Plunge: Technical Sell-Off or Sector Sentiment Shift? - AInvest

Moleculin Biotech's 48% Plunge: Technical Sell-Off or Sector Sentiment Shift?  AInvest

Moleculin Biotech's 48% Plunge: Technical Sell-Off or Sector Sentiment Shift? - AInvest

Click here to get full coverage on Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules - PR Newswire

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules  PR Newswire

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules - PR Newswire

Click here to get full coverage on MBRX gains RAMPA nod for pivotal Phase 2B/3 AnnAraC AML trial | THTX SEC Filing - Form 6-K - Stock Titan

MBRX gains RAMPA nod for pivotal Phase 2B/3 AnnAraC AML trial | THTX SEC Filing - Form 6-K  Stock Titan

MBRX gains RAMPA nod for pivotal Phase 2B/3 AnnAraC AML trial | THTX SEC Filing - Form 6-K - Stock Titan

Click here to get full coverage on Moleculin's Phase 3 AML Treatment Trial Gains Momentum: 7 Patients Treated, 16 New Sites Coming - Stock Titan

Moleculin's Phase 3 AML Treatment Trial Gains Momentum: 7 Patients Treated, 16 New Sites Coming  Stock Titan

Moleculin's Phase 3 AML Treatment Trial Gains Momentum: 7 Patients Treated, 16 New Sites Coming - Stock Titan

Click here to get full coverage on Groundbreaking Cancer Drug Data: Annamycin Demonstrates Effectiveness Against Multiple Cancer Types - Stock Titan

Groundbreaking Cancer Drug Data: Annamycin Demonstrates Effectiveness Against Multiple Cancer Types  Stock Titan

Groundbreaking Cancer Drug Data: Annamycin Demonstrates Effectiveness Against Multiple Cancer Types - Stock Titan

Click here to get full coverage on Breakthrough: Moleculin's Cancer Drug Achieves 59.4% Clinical Benefit Rate in Late-Stage Trial - Stock Titan

Breakthrough: Moleculin's Cancer Drug Achieves 59.4% Clinical Benefit Rate in Late-Stage Trial  Stock Titan

Breakthrough: Moleculin's Cancer Drug Achieves 59.4% Clinical Benefit Rate in Late-Stage Trial - Stock Titan

Click here to get full coverage on Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity - PR Newswire

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity  PR Newswire

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity - PR Newswire

Click here to get full coverage on Moleculin Biotech prices 16.08M shares at 37c in public offering - Yahoo Finance

Moleculin Biotech prices 16.08M shares at 37c in public offering  Yahoo Finance

Moleculin Biotech prices 16.08M shares at 37c in public offering - Yahoo Finance

Click here to get full coverage on Moleculin Biotech’s Annamycin Pediatric Study Approved by FDA - TipRanks

Moleculin Biotech’s Annamycin Pediatric Study Approved by FDA  TipRanks

Moleculin Biotech’s Annamycin Pediatric Study Approved by FDA - TipRanks

Click here to get full coverage on Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update  GlobeNewswire

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Click here to get full coverage on Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - GlobeNewswire

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast  GlobeNewswire

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - GlobeNewswire

Click here to get full coverage on Moleculin Biotech’s 50% Crash: A Technical Sell-Off or Sector Shift? - AInvest

Moleculin Biotech’s 50% Crash: A Technical Sell-Off or Sector Shift?  AInvest

Moleculin Biotech’s 50% Crash: A Technical Sell-Off or Sector Shift? - AInvest

Click here to get full coverage on Moleculin Biotech's $5.9M Public Offering: A Gamble on Annamycin or a Valuation Trap? - AInvest

Moleculin Biotech's $5.9M Public Offering: A Gamble on Annamycin or a Valuation Trap?  AInvest

Moleculin Biotech's $5.9M Public Offering: A Gamble on Annamycin or a Valuation Trap? - AInvest

Click here to get full coverage on Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday? - Yahoo Finance

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?  Yahoo Finance

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday? - Yahoo Finance

Click here to get full coverage on Moleculin Biotech prices $5.9 million public offering - Investing.com

Moleculin Biotech prices $5.9 million public offering  Investing.com

Moleculin Biotech prices $5.9 million public offering - Investing.com

Click here to get full coverage on Moleculin Biotech (MBRX) Rating Reiterated with $4.00 Price Target | MBRX Stock News - GuruFocus

Moleculin Biotech (MBRX) Rating Reiterated with $4.00 Price Target | MBRX Stock News  GuruFocus

Moleculin Biotech (MBRX) Rating Reiterated with $4.00 Price Target | MBRX Stock News - GuruFocus

Click here to get full coverage on Moleculin Biotech Cancels Special Stockholders Meeting - TipRanks

Moleculin Biotech Cancels Special Stockholders Meeting  TipRanks

Moleculin Biotech Cancels Special Stockholders Meeting - TipRanks

Click here to get full coverage on Moleculin Biotech’s Annamycin Trial Approved by EMA - TipRanks

Moleculin Biotech’s Annamycin Trial Approved by EMA  TipRanks

Moleculin Biotech’s Annamycin Trial Approved by EMA - TipRanks

Click here to get full coverage on Moleculin Biotech Inc.: Analyzing Its Recent Surge - StocksToTrade

Moleculin Biotech Inc.: Analyzing Its Recent Surge  StocksToTrade

Moleculin Biotech Inc.: Analyzing Its Recent Surge - StocksToTrade

Click here to get full coverage on Moleculin Participates in Virtual Investor “What This Means” Segment - GlobeNewswire

Moleculin Participates in Virtual Investor “What This Means” Segment  GlobeNewswire

Moleculin Participates in Virtual Investor “What This Means” Segment - GlobeNewswire

Click here to get full coverage on Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) - PR Newswire

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)  PR Newswire

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) - PR Newswire

Click here to get full coverage on Moleculin Announces Acceptance of Abstract to be Presented - GlobeNewswire

Moleculin Announces Acceptance of Abstract to be Presented  GlobeNewswire

Moleculin Announces Acceptance of Abstract to be Presented - GlobeNewswire

Click here to get full coverage on Moleculin Biotech, Inc. SEC 10-K Report - TradingView

Moleculin Biotech, Inc. SEC 10-K Report  TradingView

Moleculin Biotech, Inc. SEC 10-K Report - TradingView

Click here to get full coverage on Moleculin Biotech receives approval for pivotal Phase 2B/3 study of Annamycin - TipRanks

Moleculin Biotech receives approval for pivotal Phase 2B/3 study of Annamycin  TipRanks

Moleculin Biotech receives approval for pivotal Phase 2B/3 study of Annamycin - TipRanks

Click here to get full coverage on Moleculin Biotech stock hits 52-week low at $0.5 - Investing.com

Moleculin Biotech stock hits 52-week low at $0.5  Investing.com

Moleculin Biotech stock hits 52-week low at $0.5 - Investing.com

Click here to get full coverage on Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update  GlobeNewswire

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Click here to get full coverage on Moleculin Biotech Faces Nasdaq Non-Compliance Notice - TipRanks

Moleculin Biotech Faces Nasdaq Non-Compliance Notice  TipRanks

Moleculin Biotech Faces Nasdaq Non-Compliance Notice - TipRanks

Click here to get full coverage on Moleculin Biotech Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView

Moleculin Biotech Inc reports results for the quarter ended December 31 - Earnings Summary  TradingView

Moleculin Biotech Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView

Click here to get full coverage on Moleculin Biotech Releases Corporate Presentation Online - TipRanks

Moleculin Biotech Releases Corporate Presentation Online  TipRanks

Moleculin Biotech Releases Corporate Presentation Online - TipRanks

Click here to get full coverage on Moleculin Biotech, Inc. SEC 10-Q Report - TradingView

Moleculin Biotech, Inc. SEC 10-Q Report  TradingView

Moleculin Biotech, Inc. SEC 10-Q Report - TradingView

Click here to get full coverage on Moleculin Biotech Advances Clinical Trials Amid Financial Losses - TipRanks

Moleculin Biotech Advances Clinical Trials Amid Financial Losses  TipRanks

Moleculin Biotech Advances Clinical Trials Amid Financial Losses - TipRanks

Click here to get full coverage on Moleculin Biotech prices $5.9M public offering; shares down about 47% - MSN

Moleculin Biotech prices $5.9M public offering; shares down about 47%  MSN

Moleculin Biotech prices $5.9M public offering; shares down about 47% - MSN

Click here to get full coverage on Moleculin Biotech Shares Corporate Presentation Update - TipRanks

Moleculin Biotech Shares Corporate Presentation Update  TipRanks

Moleculin Biotech Shares Corporate Presentation Update - TipRanks

Click here to get full coverage on Moleculin Biotech Unveils Promising Annamycin Data at AACR - TipRanks

Moleculin Biotech Unveils Promising Annamycin Data at AACR  TipRanks

Moleculin Biotech Unveils Promising Annamycin Data at AACR - TipRanks

Click here to get full coverage on MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN

MBRX stock touches 52-week low at $1.46 amid sharp yearly decline  MSN

MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN

Click here to get full coverage on Moleculin Announces Reverse Stock Split - PR Newswire

Moleculin Announces Reverse Stock Split  PR Newswire

Moleculin Announces Reverse Stock Split - PR Newswire

Click here to get full coverage on Moleculin Biotech Gains European Approval for Phase 3 Trial - TipRanks

Moleculin Biotech Gains European Approval for Phase 3 Trial  TipRanks

Moleculin Biotech Gains European Approval for Phase 3 Trial - TipRanks

Click here to get full coverage on Transcript : Moleculin Biotech, Inc., Q1 2025 Earnings Call, May 14, 2025 - MarketScreener

Transcript : Moleculin Biotech, Inc., Q1 2025 Earnings Call, May 14, 2025  MarketScreener

Transcript : Moleculin Biotech, Inc., Q1 2025 Earnings Call, May 14, 2025 - MarketScreener

Click here to get full coverage on Moleculin receives Georgian approval for pivotal AML treatment trial By Investing.com - Investing.com India

Moleculin receives Georgian approval for pivotal AML treatment trial By Investing.com  Investing.com India

Moleculin receives Georgian approval for pivotal AML treatment trial By Investing.com - Investing.com India

Click here to get full coverage on Moleculin Biotech receives positive FDA guidance for acceleration of AML trial - TipRanks

Moleculin Biotech receives positive FDA guidance for acceleration of AML trial  TipRanks

Moleculin Biotech receives positive FDA guidance for acceleration of AML trial - TipRanks

Click here to get full coverage on Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation - Yahoo Finance

Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation  Yahoo Finance

Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation - Yahoo Finance

Click here to get full coverage on Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies - Nasdaq

Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies  Nasdaq

Moleculin Biotech Inc (MBRX)

Price Chart

Key Statistics

Technicals

About MBRX

Latest News

Moleculin Biotech Surges 19.5%—What's Fueling the Rally? - AInvest

Insider Purchase: Chief Financial Officer of $MBRX Buys 270,270 Shares - Nasdaq

Favourable Signals For Moleculin Biotech: Numerous Insiders Acquired Stock - simplywall.st

Advanced Charts

Top Gainers

Top Losers